Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.62 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27313202 | 0.98 | MAOB (0.60) | MAOBGRM5MEN1KMT2AALOX5 | |
| SCHEMBL308991 | 0.87 | MAOB (0.72) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL10046165 | 0.87 | MAOB (0.72) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL1072784 | 0.87 | GRM5 (0.62) | MAOBGRM5MEN1KMT2AALOX5 | |
| SCHEMBL13841458 | 0.87 | GRM5 (0.62) | MAOBGRM5MEN1KMT2AALOX5 | |
| SCHEMBL24628112 | 0.87 | MAOB (0.74) | MAOBGRM5 | |
| SCHEMBL14339782 | 0.84 | GRM5 (0.59) | MAOBGRM5MEN1KMT2AALOX5 | |
| SCHEMBL14218089 | 0.84 | GRM5 (0.59) | MAOBGRM5MEN1KMT2AALOX5 | |
| SCHEMBL24628109 | 0.83 | MAOB (0.68) | MAOB | |
| SCHEMBL7743406 | 0.83 | MAOB (0.67) | MAOBMEN1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745255-B2 | Meta-substituted biphenyl peripherally restricted FAAH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20140288170-A1 | META-SUBSTITUTED BIPHENYL PERIPHERALLY RESTRICTED FAAH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-25 | — | — | US | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| CN-101006087-B | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER | 2010-09-29 | — | — | CN | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| CN-101006087-A | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1778686-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018718-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | MAOB 536/4885GRM5 286/4885MEN1 374/4885 |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAOB 2207/4885GRM5 2739/4885MEN1 4865/4885 |
| US-20140288170-A1 | META-SUBSTITUTED BIPHENYL PERIPHERALLY RESTRICTED FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MAOB 233/4885GRM5 360/4885MEN1 4382/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAOB 2147/4885GRM5 2790/4885MEN1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.